Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?

被引：0
|
作者：
Landi, Lorenza [1 ]
Cappuzzo, Federico [1 ]
机构：
[1] Osped Civile Livorno, Ist Toscano Tumori, I-57100 Livorno, Italy
来源：
JOURNAL OF THORACIC DISEASE | 2012年 / 4卷 / 02期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; ERLOTINIB; GEFITINIB;
D O I：
10.3978/j.issn.2072-1739.2012.03.04
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：226 / 228
页数：3
相关论文
共 50 条
  • [1] THERAPEUTIC STRATEGIES IN THE 1ST-LINE TREATMENT OF PATIENTS WITH NSCLC HARBORING EGFR MUTATIONS
    Rapti, Angeliki
    ANTICANCER RESEARCH, 2014, 34 (10) : 6129 - 6130
  • [2] First-line gefitinib for elderly patients harboring EGFR mutations
    Asami, K.
    Koizumi, T.
    Amejima, S.
    Morikawa, A.
    Morozumi, N.
    Hirai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A PHASE II STUDY OF ERLOTINIB AS FIRST-LINE TREATMENT IN JAPANESE ADVANCED NSCLC PATIENTS HARBORING EGFR MUTATIONS
    Horiike, A.
    Nishio, M.
    Goto, K.
    Yamamoto, N.
    Chikamori, K.
    Maemondo, M.
    Hida, T.
    Katakami, N.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 413 - 413
  • [4] Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line-Is There a Difference?
    Mok, Tony
    Yang, Jin-Ji
    Lam, Kwok-Chi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 1081 - 1088
  • [5] First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?
    Passaro, Antonio
    Spitaleri, Gianluca
    de Marinis, Filippo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (08) : 799 - 801
  • [6] Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
    Oscar Arrieta
    Rodrigo Catalán
    Silvia Guzmán-Vazquez
    Feliciano Barrón
    Luis Lara-Mejía
    Herman Soto-Molina
    Maritza Ramos-Ramírez
    Diana Flores-Estrada
    Jaime de la Garza
    BMC Cancer, 20
  • [7] Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
    Arrieta, Oscar
    Catalan, Rodrigo
    Guzman-Vazquez, Silvia
    Barron, Feliciano
    Lara-Mejia, Luis
    Soto-Molina, Herman
    Ramos-Ramirez, Maritza
    Flores-Estrada, Diana
    de la Garza, Jaime
    BMC CANCER, 2020, 20 (01)
  • [8] Efficacy and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Minemura, H.
    Sugiyama, T.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Minato, K.
    Kaburagi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S943 - S943
  • [9] Treatment of NSCLC Patients with Malignant Pleural Effusion Harboring Exon 19 and 21 EGFR Mutations after First-Line and Second-Line TKIs
    Zheng, Zhen
    Jin, Xiance
    Xie, Congying
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1245 - S1246
  • [10] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
    Bria, E.
    Milella, M.
    Cuppone, F.
    Novello, S.
    Ceribelli, A.
    Vaccaro, V.
    Sperduti, I.
    Gelibter, A.
    Scagliotti, G. V.
    Cognetti, F.
    Giannarelli, D.
    ANNALS OF ONCOLOGY, 2011, 22 (10) : 2277 - 2285
12345